German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease, osteogenesis imperfecta (OI).\n\n\n\nAlso called brittle bone disease, the condition is currently lacking approved drugs.\n\n\n\nSirana Pharma focuses on the development of treatments for unmet medical needs in muscle and bone diseases. The collaboration will utilize Sirana\u2019s microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue. \n\n\n\n\u201cCombining Sirana\u2019s novel miRNA-targeting approach, and the long-standing experience in musculoskeletal disorders and disease mechanisms of its founders, with the expertise and competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the treatment of this rare disease and to identify potential candidates for further development,\u201d said Michael Kring, CEO of Sirana Pharma GmbH. \n\n\n\n\u201cAt Pfizer, we are committed to advancing promising, emerging research \u2013 both through our internal capabilities and through collaborations with companies like Sirana \u2013 with the goal of bringing potentially life-changing medicines to patients around the world,\u201d said Seng H. Cheng, senior vice president and chief scientific officer, Pfizer Rare Disease. \n\n\n\n\u201cWe look forward to working together with the Sirana team to further explore this new and innovative investigational approach, utilizing miRNA-targeting for the potential treatment of rare bone diseases.\u201d \n\n\n\nOsteogenesis imperfecta\n\n\n\nAlso known as brittle bone disease, osteogenesis imperfecta is a genetic disorder that causes weak bones that break easily in addition to other symptoms. There are several forms of OI, and although there is no cure, OI symptoms can be managed with a healthy lifestyle, medication, or surgery.\n\n\n\nAccording to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the condition is a genetic or heritable disease in which bones break easily, often with no obvious cause or injury. Symptoms can range from mild with only a few fractures to severe with many medical complications.\n\n\n\nThere are more than eight types of the disease, and those with a family history of it are at greater risk due to an abnormal gene passed on from one or both parents. \n\n\n\nSirana Pharma, based in Munich, is focusing on the development of first-in-class molecules to treat sarcopenia \u2013 age related muscle weakness - and osteogenesis imperfecta \u2013 inherited brittle bone disease (an orphan drug indication).